HBMN:SWX
HBM Healthcare Investments AG
228,50 CHF
arrow_downward
-1,51%(-3,50) 1 d.
30. apr., 10:14:27 GMT+2 · CHF
search
Visi simboli
1 d.
5 d.
1 m.
6 m.
Š.g.
1 g.
5 g.
Maks.
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: HBMN…
Atvērt
231,50 CHF
Augsta
231,50 CHF
Zema
228,00 CHF
Tirgus kapitalizācija
1,54 mljrd.
Vid. apjoms
6,47 tūkst.
Apjoms
401,00
Dividende
3,28%
Ceturkšņa dividendes
1,87 CHF
Datums, kad tiek pārtraukta dividenžu izmaksa
2025. gada 2. jūl.
Cenas/peļņas attiecība
6,36
Augstākā 52 ned.
245,50 CHF
Zemākā 52 ned.
157,40 CHF
Peļņa uz vienu akciju
35,93 CHF
Apgrozībā esošās akcijas
6,74 milj.
Ziņas un raksti
No avotiem tīmeklī
MarketBeat
·
pirms 9 minūtēm
Ames National (NASDAQ:ATLO) Stock Passes Above 200 Day Moving Average - Time to Sell?
StockStory
·
pirms 47 minūtēm
Winners And Losers Of Q4: Health Catalyst (NASDAQ:HCAT) Vs The Rest Of The Data Analytics Stocks
富途牛牛
·
pirms 1 stundas
Dow Jones Top Company Headlines at 3 AM ET: Meta Reports Big Revenue Jump and Projected Spending Increase | White ...
Investor's Business Daily
·
pirms 5 stundām
Tech Futures Rise On Titans' Results And CapEx Plans
Profils
HBM Healthcare Investments is a publicly traded Swiss investment and venture capital firm focusing on emerging technologies in the global healthcare sector. Within healthcare their focus is predominantly in biotechnology, medical technology, diagnostics, therapeutics and digital health.
A 2022 article in Swiss daily Luzerner Zeitung profiled HBM and interviewed its CEO, and described the company’s investment strategy as focused on early-stage but post-seed round opportunities.
Founded in July 2001 as HBM Bioventures AG by former Roche Chief Financial Officer Henri B. Meier who was its first Chairperson of the Board. A Handelszeitung article from 2020 described Meier's goal when founding the company as to profit from the "thesis" that from the 2000s onwards "Big Pharma is doing less and less research and development itself and is instead acquiring promising biotech companies" In an analysis of how HBM was put together, Swiss magazine Finanz und Wirtschaft described how he was able to raise almost 500 million Swiss Francs for the company launch. HBM is based in Zug and managed by HBM Partners. HBM acquired rival Swiss VC International BM Biomedicine in 2005. Wikipedia
Par “HBM Healthcare Investments AG”
Ģenerāldirektors-
Darbinieki-
Dibināšanas datums2001. gada 12. jūl.
Galvenais birojsCūga, Cūga, Šveice
Sektors-
Tīmekļa vietnehbmhealthcare.com
MI saturā var būt kļūdas. Uzzināt vairāk